TargetBeta
NLRP3
NLR family pyrin domain containing 3 · also AGTAVPRL, AII, AVP, FCAS · NLR family
3 programs in company-led studies act on NLRP3, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| parunoflast | Eli Lilly | inhibitor | phase 2 | 31 running | – | a judged reading |
| abdenoflast | Eli Lilly | inhibitor | phase 2 | 21 running | – | a judged reading |
| ACI-19764rule | AC Immune | inhibitor | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Obesity, 2 programs
- Cryopyrin-Associated Periodic Syndromes, 1 program
- Parkinson Disease, 1 program
- Pericarditis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026ACI-19764 · AC Immune · phase 1 · NCT07463196
- Jan 2027parunoflast · Eli Lilly · phase 2 · NCT07867340
- Oct 2027abdenoflast · Eli Lilly · phase 2 · NCT06836232
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.